Cocrystal Pharma Inc (STU:8CC)
€ 1.96 -0.01 (-0.51%) Market Cap: 20.23 Mil Enterprise Value: 9.68 Mil PE Ratio: 0 PB Ratio: 1.68 GF Score: 36/100

Cocrystal Pharma Inc Virtual Investor Summit Transcript

Mar 29, 2023 / 02:30PM GMT
Release Date Price: €1.63 (-1.21%)
Gage Greeno
Ascent Conference - Moderator

Good morning, everyone, and welcome back to the Investor Summit March event. Presenting now is Jim Martin, Co-CEO and CFO of Cocrystal Pharma. Jim, I'm going to let you go ahead and get started.

Jim Martin
Cocrystal Pharma, Inc. - Interim Co-CEO & CFO

All right, great. Thank you everyone for your interest in Cocrystal. Thank you, Investor Summit for having us. I'll get started right away. So Cocrystal is a therapeutic antiviral company. I want to make that clear, we are not a vaccine company. We actually target the virus once it enters the body. And as I'll get into, we target the replication of these viruses. We have very advanced programs in clinical stage. We also have very validated mechanisms of action and our proprietary drug discovery platform, which was derived from our Nobel Laureate founder. It has been the core of our programs.

Investor highlights are that we target multibillion global markets for the treatment of both acute and pandemic diseases. These are compounds that are derived off of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot